Grzegorz Bulaj

Dr. Grzegorz Bulaj

Department of Medicinal Chemistry, Skaggs Pharmacy Institute, University of Utah, Salt Lake City, UT 84112, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
GBGrzegorz Bulaj
Grzegorz Bulaj
BOBaldomero M. Olivera
Baldomero M. Olivera
Conopeptides from >700 species of predatory marine Conus snails provide an impressive molecular diversity of cysteine-rich peptides. Most of the estimated 50,000-100,000 distinct conopeptides range in size from 10 to 50 amino acid residues, often with multiple posttranslational modifications. The great majority contain from two to four disulfide bridges. As the biosynthetic and chemical production of this impressive repertoire of disulfide-rich peptides has been investigated, particularly the formation of native disulfide bridges, differences between in vivo and in vitro oxidative folding have become increasingly evident. In this article, we provide an overview of the molecular diversity of conotoxins with an emphasis on the cysteine patterns and disulfide frameworks. The conotoxin folding studies reviewed include regioselective and direct oxidation strategies, recombinant expression, optimization of folding methods, mechanisms of in vitro folding, and preliminary data on the biosynthesis of conotoxins in venom ducts. Despite these studies, how the cone snails efficiently produce properly folded conotoxins remains unanswered. As chemists continue to master oxidative folding techniques, insights gleaned from how conotoxins are folded in vivo will likely lead to the development of the new folding methods, as well as shed some light on fundamental mechanisms relevant to the protein folding problem.

3 March 2009 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AWAleksandra Walewska
Aleksandra Walewska
MZMin‐Min Zhang
Min‐Min Zhang
JSJack J. Skalicky
Jack J. Skalicky
DYDoju Yoshikami
Doju Yoshikami
BOBaldomero M. Olivera
Baldomero M. Olivera
GBGrzegorz Bulaj
Grzegorz Bulaj

22 February 2010 in Biochemistry
Verified
Journal Article
Closed access
KGKonkallu Hanumae Gowd
Konkallu Hanumae Gowd
VYViktor Yarotskyy
Viktor Yarotskyy
KEKeith S. Elmslie
Keith S. Elmslie
JSJack J. Skalicky
Jack J. Skalicky
BOBaldomero M. Olivera
Baldomero M. Olivera
GBGrzegorz Bulaj
Grzegorz Bulaj

21 November 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GBGrzegorz Bulaj
Grzegorz Bulaj
BGBrad R. Green
Brad R. Green
HLHee-Kyoung Lee
Hee-Kyoung Lee
CRCharles R. Robertson
Charles R. Robertson
KWKaren White
Karen White
HWH. Steve White
H. Steve White

11 March 2009 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
THTiffany S. Han
Tiffany S. Han
MZMin‐Min Zhang
Min‐Min Zhang
AWAleksandra Walewska
Aleksandra Walewska
PGPawel Gruszczynski
Pawel Gruszczynski
CRCharles R. Robertson
Charles R. Robertson
GBGrzegorz Bulaj
Grzegorz Bulaj

1 May 2018 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
PDF file
PAPegah Afra
Pegah Afra
CBCarol S. Bruggers
Carol S. Bruggers
MSMatthew Sweney
Matthew Sweney
LFLilly Fagatele
Lilly Fagatele
FAFareeha Alavi
Fareeha Alavi
GBGrzegorz Bulaj
Grzegorz Bulaj
Digital health technologies for people with epilepsy (PWE) include internet-based resources and mobile apps for seizure management. Since non-pharmacological interventions, such as listening to specific Mozart's compositions, cognitive therapy, psychosocial and educational interventions were shown to reduce epileptic seizures, these modalities can be integrated into mobile software and delivered by mobile medical apps as digital therapeutics. Herein, we describe: (1) a survey study among PWE about preferences to use mobile software for seizure control, (2) a rationale for developing digital therapies for epilepsy, (3) creation of proof-of-concept mobile software intended for use as an adjunct digital therapeutic to reduce seizures, and (4) broader applications of digital therapeutics for the treatment of epilepsy and other chronic disorders. A questionnaire was used to survey PWE with respect to preferred features in a mobile app for seizure control. Results from the survey suggested that over 90% of responders would be interested in using a mobile app to manage their seizures, while 75% were interested in listening to specific music that can reduce seizures. To define digital therapeutic for the treatment of epilepsy, we designed and created a proof-of-concept mobile software providing digital content intended to reduce seizures. The rationale for all components of such digital therapeutic is described. The resulting web-based app delivered a combination of epilepsy self-care, behavioral interventions, medication reminders and the antiseizure music, such as the Mozart's sonata K.448. To improve long-term patient engagement, integration of mobile medical app with music and multimedia streaming via smartphones, tablets and computers is also discussed. This work aims toward development and regulatory clearance of software as medical device (SaMD) for seizure control, yielding the adjunct digital therapeutic for epilepsy, and subsequently a drug-device combination product together with specific antiseizure medications. Mobile medical apps, music, therapeutic video games and their combinations with prescription medications present new opportunities to integrate pharmacological and non-pharmacological interventions for PWE, as well as those living with other chronic disorders, including depression and pain.